Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 12;2012(9):CD010111.
doi: 10.1002/14651858.CD010111.

Topical capsaicin (low concentration) for chronic neuropathic pain in adults

Sheena Derry  1 , R Andrew Moore
Affiliations

Topical capsaicin (low concentration) for chronic neuropathic pain in adults

Sheena Derry et al. Cochrane Database Syst Rev. .

Abstract

Background: Topical creams with capsaicin are used to treat pain from a wide range of chronic conditions including neuropathic pain. Following application to the skin capsaicin causes enhanced sensitivity to noxious stimuli, followed by a period with reduced sensitivity and, after repeated applications, persistent desensitisation. There is uncertainty about the efficacy and tolerability of capsaicin for treating painful chronic neuropathies. This is an update of an earlier review of topical capsaicin for chronic neuropathic pain in adults that looked at all doses and formulations of capsaicin. The original review has now been split: here we consider only formulations using a low concentration of capsaicin (< 1%) applied several times daily over several weeks, while another review will consider a single application of capsaicin at a high concentration.

Objectives: To review the evidence from controlled trials on the efficacy and tolerability of topically applied low-concentration (< 1%) capsaicin in chronic neuropathic pain in adults.

Search methods: Cochrane CENTRAL, MEDLINE, EMBASE and Oxford Pain Relief Database, searched to July 2012.

Selection criteria: Randomised, double-blind, placebo-controlled studies of at least six weeks' duration, using low-concentration (< 1%) topical capsaicin to treat neuropathic pain.

Data collection and analysis: Two review authors independently assessed study quality and validity, and extracted data. Information was extracted on numbers of participants with pain relief (clinical improvement) after at least six weeks, and with local skin reactions, and used to calculate relative risk (or risk ratio, RR) and numbers needed to treat to benefit (NNT) and harm (NNH). Details of definition of pain relief and specific adverse events were sought.

Main results: No additional studies were identified for this update of low concentration capsaicin. Included studies were published before 1996. Six studies (389 participants in total) compared regular application of low dose (0.075%) capsaicin cream with placebo cream. There was substantial heterogeneity in results, probably as a result of the small number of studies each with small numbers of participants, as well as the different pain conditions studied and different definitions of "clinical success" reported. Only two studies reported data for the preferred primary outcome of at least 50% pain relief, and there were too few data for pooled analysis. Local skin reactions were more common with capsaicin, usually tolerable, and attenuated with time; the NNH for repeated low-dose application was 2.5 (95% confidence interval (CI) 2.1 to 3.1). All studies satisfied minimum criteria for quality and validity, but maintenance of blinding remains a potential problem.

Authors' conclusions: There were insufficient data to draw any conclusions about the efficacy of low-concentration capsaicin cream in the treatment of neuropathic pain. The information we have suggests that low-concentration topical capsaicin is without meaningful effect beyond that found in placebo creams; given the potential for bias from small study size, this makes it unlikely that low-concentration topical capsaicin has any meaningful use in clinical practice. Local skin irritation, which was often mild and transient but may lead to withdrawal, was common. Systemic adverse effects were rare.

PubMed Disclaimer

Conflict of interest statement

RAM and SD have received research support from charities, government and industry sources at various times. RAM has consulted for various pharmaceutical companies and received lecture fees from pharmaceutical companies related to analgesics and other healthcare interventions. No pharmaceutical company had any involvement with this review.

Figures

1
1
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
2
2
Forest plot of comparison: 1 Capsaicin 0.075% versus placebo, outcome: 1.1 Clinical improvement.
3
3
L'Abbé plot showing response rates for any improvement in studies using low‐concentration capsaicin. Size of circle is proportional to size of study (inset scale). Blue circles are studies reporting the outcome of ≥ 50% pain relief.
4
4
Forest plot of comparison: 1 Capsaicin 0.075% versus placebo, outcome: 1.2 Adverse event: burning, stinging, erythema.
1.1
1.1. Analysis
Comparison 1 Capsaicin 0.075% versus placebo, Outcome 1 Clinical improvement.
1.2
1.2. Analysis
Comparison 1 Capsaicin 0.075% versus placebo, Outcome 2 Adverse event: burning, stinging, erythema.
1.3
1.3. Analysis
Comparison 1 Capsaicin 0.075% versus placebo, Outcome 3 Adverse event: coughing, sneezing.
1.4
1.4. Analysis
Comparison 1 Capsaicin 0.075% versus placebo, Outcome 4 Adverse event withdrawal.
See this image and copyright information in PMC

References

References to studies included in this review

Bernstein 1989 {published data only}
    1. Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE. Topical capsaicin treatment of chronic postherpetic neuralgia. Journal of the American Academy of Dermatology 1989;21(2):265‐70. - PubMed
Biesbroeck 1995 {published data only}
    1. Biesbroeck R, Bril V, Hollander P, Kabadi U, Schwartz S, Singh SP, et al. A double‐blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Advances in Therapy 1995;12(2):111‐20. - PubMed
CSG 1992 {published data only}
    1. Basha KM, Whitehouse FW. Capsaicin: a therapeutic option for painful diabetic neuropathy. Henry Ford Hospital Medical Journal 1991;39:138‐40. - PubMed
    1. Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992;15(2):159‐65. - PubMed
    1. Donofrio P, Walker F, Hunt V, Tandan R, Fries T, Lewis G, et al. Treatment of painful diabetic neuropathy with topical capsaicin: a multicenter, double‐blind, vehicle‐controlled study. Archives of Internal Medicine 1991;151:2225‐9. - PubMed
    1. Scheffler NM, Sheitel PL, Lipton MN. Treatment of painful diabetic neuropathy with capsaicin 0.075%. Journal of the American Podiatric Medical Association 1991;81:288‐93. - PubMed
    1. Tandan R, Lewis GA, Krusinski PB, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy. Controlled study with long‐term follow‐up. Diabetes Care 1992;15:8‐14. - PubMed
Ellison 1997 {published data only}
    1. Ellison N, Loprinzi CL, Kugler J, Hatfield AK, Miser A, Sloan JA, et al. Phase III placebo‐controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. Journal of Clinical Oncology 1997;15(8):2974‐80. - PubMed
Low 1995 {published data only}
    1. Low PA, Opfer‐Gehrking TL, Dyck PJ, Litchy WJ, O'Brien PC. Double‐blind, placebo‐controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain 1995;62(2):163‐8. - PubMed
Watson 1992 {published data only}
    1. Watson CP, Evans RJ. The postmastectomy pain syndrome and topical capsaicin: a randomized trial. Pain 1992;51(3):375‐9. - PubMed
Watson 1993 {published data only}
    1. Watson CP, Tyler KL, Bickers DR, Millikan LE, Smith S, Coleman E. A randomized vehicle‐controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clinical Therapeutics 1993;15(3):510‐26. - PubMed

References to studies excluded from this review

Chad 1990 {published data only}
    1. Chad DA, Aronin N, Lundstrom R, McKeon P, Ross D, Molitch M, et al. Does capsaicin relieve the pain of diabetic neuropathy?. Pain 1990;42(3):387‐8. - PubMed
Fusco 1992 {published data only}
    1. Fusco BM, Alessandri M. Analgesic effect of capsaicin in idiopathic trigeminal neuralgia. Anesthesia and Analgesia 1992;74:375‐7. - PubMed
McCarty 1994 {published data only}
    1. McCarty DJ, Csuka M, McCarthy G, Trotter D. Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Seminars in Arthritis and Rheumatism 1994;23(Suppl 3):41‐7.
McCleane 2000 {published data only}
    1. McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double‐blind, placebo‐controlled study. British Journal of Clinical Pharmacology 2000;49(6):574‐9. - PMC - PubMed
Paice 2000 {published data only}
    1. Paice JA, Ferrans CE, Lashley FR, Shott S, Vizgirda V, Pitrak D. Topical capsaicin in the management of HIV‐associated peripheral neuropathy. Journal of Pain and Symptom Management 2000;19(1):45‐52. - PubMed
Peikert 1991 {published data only}
    1. Peikert A, Hentrich M, Ochs G. Topical 0.025% capsaicin in chronic post‐herpetic neuralgia: efficacy, predictors of response and long‐term course. Journal of Neurology 1991;238:452‐6. - PubMed
Pfeifer 1993 {published data only}
    1. Pfeifer MA, Ross DR, Schrage JP, Gelber DA, Schumer MP, Crain GM, et al. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 1993;16:1103‐15. - PubMed
Robbins 1998 {published data only}
    1. Robbins WR, Staats PS, Levine J, Fields HL, Allen RW, Campbell JN, et al. Treatment of intractable pain with topical large‐dose capsaicin: preliminary report. Anesthesia and Analgesia 1998;86:579‐83. - PubMed
Vickers 1998 {published data only}
    1. Vickers ER, Cousins MJ, Walker S, Chisholm K. Analysis of 50 patients with atypical odontalgia. A preliminary report on pharmacological procedures for diagnosis and treatment. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 1998;85:24‐32. - PubMed
Watson 1988 {published data only}
    1. Watson CP, Evans RJ, Watt VR. Post‐herpetic neuralgia and topical capsaicin. Pain 1988;33:333‐40. - PubMed
Watson 1989 {published data only}
    1. Watson CP, Evans RJ, Watt VR. The post‐mastectomy pain syndrome and the effect of topical capsaicin. Pain 1989;38:177‐86. - PubMed

References to ongoing studies

NCT00993070 {published data only}
    1. Efficacy and safety study of topical capsaicin in painful diabetic neuropathy. www.clinicaltrials.gov [accessed 10 August 2012] 2012.

Additional references

Anand 2011
    1. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high‐concentration capsaicin 8% patch. British Journal of Anaesthesia 2011;107(4):490–502. [DOI: ] - PMC - PubMed
Attal 2010
    1. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology 2010;17(9):1113‐e88. [DOI: 10.1111/j.1468-1331.2010.02999.x] - DOI - PubMed
AUREF 2012
    1. Cochrane Pain, Palliative and Supportive Care Group. PaPaS author and referee guidance. http://papas.cochrane.org/papas‐documents [Accessed 11 August 2012].
BNF 2012
    1. Rubefacients, topical NSAIDs, capsaicin, and poultices. In: Martin J, Ryan RSM editor(s). British National Formulary. Vol. 62, London: BMJ Group and RPS Publishing, 2012:676‐8. [ISBN: 978‐0‐85369‐981‐1]
Bril 2011
    1. Bril V, England J, Franklin GM, Backonja M, Cohen J, Toro D, et al. Evidence‐based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76(20):1758‐65. [DOI: 10.1212/WNL.0b013e3182166ebe] - DOI - PMC - PubMed
Collins 1997
    1. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain 1997;72(1‐2):95‐7. - PubMed
Cook 1995
    1. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ (Clinical Research Ed) 1995;310:452‐4. - PMC - PubMed
Dworkin 2008
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] - DOI - PubMed
Edwards 1999
    1. Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. Journal of Pain and Symptom Management 1999;18(6):427‐37. [DOI: 10.1016/S0885-3924(99)00093-7] - DOI - PubMed
Gustorff 2008
    1. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self‐reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132‐6. - PubMed
Hall 2006
    1. Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain 2006;122(1‐2):156‐62. [DOI: 10.1016/j.pain.2006.01.030] - DOI - PubMed
Ioannidis 2001
    1. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285(4):437‐43. - PubMed
Jadad 1996a
    1. Jadad AR, Carroll D, Moore A, McQuay H. Developing a database of published reports of randomised clinical trials in pain research. Pain 1996;66:239‐46. - PubMed
Jadad 1996b
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1‐12. - PubMed
L'Abbe 1987
    1. L'Abbé KA, Detsky AS, O'Rourke K. Meta‐analysis in clinical research. Annals of Internal Medicine 1987;107:224‐33. - PubMed
Loke 2001
    1. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials ‐ a systematic survey. BMC Clinical Pharmacology 2001;1:3. [DOI: 10.1186/1472-6904-1-3] - DOI - PMC - PubMed
Martindale 2012
    1. Martindale: the complete drug reference [online]. At: www.medicinescomplete.com/mc/martindale/current/ [accessed 10 August 2012].
Mason 2004
    1. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ (Clinical Research Ed) 2004;328(7446):991. - PMC - PubMed
McQuay 2007
    1. McQuay HJ, Smith LA, Moore RA. Chronic pain. In: Stevens A, Raferty J, Mant J, Simpson S editor(s). Health Care Needs Assessment. Oxford: Radcliffe Publishing Ltd, 2007:519‐600. [ISBN: 978‐1‐84619‐063‐6]
Moore 1998a
    1. Moore RA, Tramèr MR, Carroll D, Wiffen PJ, McQuay HJ. Quantitative systematic review of topically applied non‐steroidal anti‐inflammatory drugs. BMJ 1998;316(7128):333‐8. - PMC - PubMed
Moore 1998b
    1. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209‐16. [DOI: 10.1016/S0304-3959(98)00140-7] - DOI - PubMed
Moore 2008
    1. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐23. [ISBN: 978‐0‐931092‐69‐5]
Moore 2009
    1. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] - DOI - PMC - PubMed
Moore 2010
    1. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] - DOI - PubMed
Moore 2012
    1. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] - DOI - PubMed
Morris 1995
    1. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG editor(s). Statistics with Confidence ‐ Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1995:50‐63. - PMC - PubMed
NICE 2010
    1. National Institute for Health and Clinical Excellence. Neuropathic Pain: the Pharmacological Management of Neuropathic Pain in Adults in Non‐specialist Settings. London: National Institute for Health and Clinical Excellence, 2010. [online: www.nice.org.uk/guidance/CG96] - PubMed
Nuesch 2010
    1. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515] - DOI - PMC - PubMed
Ohayon 2012
    1. Ohayon MM, Stingle JC. Prevalence and comorbidity of chronic pain in the German general population. Journal of Psychiatric Research 2012;46(4):444‐50. [DOI: 10.1016/j.jpsychires.2012.01.001] - DOI - PubMed
PCA 2011
    1. Anon. Prescription Cost Analysis, England 2011. The NHS Information Centre, 2012. [ISBN: I978‐1‐84636‐685‐7]
Phillips 2010
    1. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV‐associated sensory neuropathy: a systematic review and meta‐analysis of randomised controlled trials. PLoS One 2010;5(12):e14433. [DOI: 10.1371/journal.pone.0014433] - DOI - PMC - PubMed
Rains 1995
    1. Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post‐herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging 1995;7(4):317‐28. - PubMed
Sadosky 2008
    1. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Practice 2008;8(1):45‐56. [DOI: 10.1111/j.1533-2500.2007.00164.x] - DOI - PubMed
Smith 2011
    1. Smith HS, Argoff CE. Pharmacological treatment of diabetic neuropathic pain. Drugs 2011;71(5):557‐89. [DOI: 10.2165/11588940-000000000-00000] - DOI - PubMed
Straube 2010
    1. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia ‐ responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150] - DOI - PMC - PubMed
Sultan 2008
    1. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29] - DOI - PMC - PubMed
Toth 2009
    1. Toth C, Lander J, Wiebe S. The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Medicine 2009;10(5):918‐29. [DOI: 10.1111/j.1526-4637.2009.00655.x] - DOI - PubMed
Watson 1998
    1. Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998;51(4):1166‐71. - PubMed
Yawn 2009
    1. Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Medicine 2009;10(3):586‐93. [DOI: 10.1111/j.1526-4637.2009.00588.x] - DOI - PMC - PubMed

References to other published versions of this review

Derry 2009
    1. Derry S, Lloyd R, Moore RA, McQuay H. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007393.pub2] - DOI - PMC - PubMed

Publication types

MeSH terms